<DOC>
	<DOCNO>NCT00401570</DOCNO>
	<brief_summary>This clinical trial conduct determine tumor response preliminary safety monoclonal antibody specifically bind cell surface receptor ( α5β1 integrin ) require establishment new blood vessel tumor growth , process know angiogenesis .</brief_summary>
	<brief_title>A Study Volociximab Combination With Gemcitabine Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female , 18 year age old . Histologically cytologically confirm metastatic adenocarcinoma pancreas . May receive prior immunotherapy ( include monoclonal antibody ) vaccine therapy . Measurable disease , accord RECIST criterion . Negative pregnancy test ( woman childbearing potential ) . Pretreatment laboratory level meet specific criterion . Prior treatment Volociximab ( M200 ) inhibitor α5β1 integrin ( antibody small molecule ) gemcitabine chemotherapeutic regimen . Known hypersensitivity murine proteins chimeric antibody component product . Use investigational drug within 4 week prior screen 5 halflives prior investigational drug ( whichever longer ) . Monoclonal antibody therapy within 4 week first dose Volociximab . Central Nervous System ( CNS ) tumor metastasis . History bleed disorder within past year . Medical condition may exacerbate bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Antibody</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic</keyword>
</DOC>